GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » YoY Rev. per Sh. Growth

CureVac NV (WBO:CVAC) YoY Rev. per Sh. Growth : 25.42% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. CureVac NV's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2023 was 25.42%.

CureVac NV's Revenue per Share for the three months ended in Sep. 2023 was €0.07.


CureVac NV YoY Rev. per Sh. Growth Historical Data

The historical data trend for CureVac NV's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV YoY Rev. per Sh. Growth Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
YoY Rev. per Sh. Growth
- 35.62 273.74 49.73 -35.56

CureVac NV Quarterly Data
Dec18 Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.42 -72.40 -73.85 -68.52 25.42

CureVac NV YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

CureVac NV's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2022 )
=(Revenue per Share (A: Dec. 2022 )-Revenue per Share (A: Dec. 2021 ))/ | Revenue per Share (A: Dec. 2021 ) |
=(0.357-0.554)/ | 0.554 |
=-35.56 %

CureVac NV's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Sep. 2023 )
=(Revenue per Share (Q: Sep. 2023 )-Revenue per Share (Q: Sep. 2022 )) / | Revenue per Share (Q: Sep. 2022 )) |
=(0.074-0.059)/ | 0.059 |
=25.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of CureVac NV's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (WBO:CVAC) Business Description

Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.